drugset

drugset / Trial / NCT04605926

A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19

NCT04605926 ↗

Phase 3 Withdrawn Biocon Limited

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized controlled trial to evaluate the efficacy and safety of itolizumab in subjects hospitalized with COVID-19.

Timeline

Start: 2020-11
Primary completion: 2021-04
Completion: 2021-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Itolizumab	Monoclonal antibody	—	Intravenous

Indications